Zevtera (ceftobiprole) / Basilea, MedCap AB - LARVOL DELTA

PAC CEF: Pharmacokinetics of High-dose Ceftobiprole in Community-acquired Pneumonia Under Mechanical Ventilation. (clinicaltrials.gov) - P=N/A | N=12 | Completed | Sponsor: Centre Hospitalier Universitaire de Nīmes | Not yet recruiting ➔ Completed

Trial completion • Infectious Disease • Pneumonia • Respiratory Diseases

How to use novel antimicrobials beyond official indications: an expert consensus. (PubMed, JAC Antimicrob Resist) - "The process comprised three survey rounds evaluating off-label uses of eight drugs: ceftazidime-avibactam, ceftolozane-tazobactam, cefiderocol, ceftaroline, ceftobiprole, dalbavancin, tedizolid, and isavuconazole. The guidance prioritizes targeted treatment over empirical use, aligning with international ASP principles and WHO recommendations. These results provide a regional reference to optimize ASP initiatives focus on new antibiotic use while minimizing ecological impact and resistance development."

Journal • Cardiovascular • Critical care • Infectious Disease

Ceftobiprole alone versus ampicillin-ceftriaxone against borderline-penicillin-resistant, ampicillin-susceptible, and vancomycin-resistant Enterococcus faecalis isolates. (PubMed, Antimicrob Agents Chemother) - "When tested at ampicillin inhibitory concentrations, ceftobiprole-ampicillin activity trended towards antagonism in two isolates. Overall, ceftobiprole alone had greater activity compared to ampicillin-ceftriaxone, and there may be a potential role of ceftobiprole combination therapy in certain isolates."

Journal • Cardiovascular

Pharmacokinetic modeling and efficacy of ceftobiprole medocaril against pneumonic tularemia in cynomolgus macaques. (PubMed, Antimicrob Agents Chemother) - "By comparison, animals receiving 1.33 mg/kg treatments with ceftobiprole medocaril exhibited a 50% survival rate, and animals receiving either of the higher doses exhibited an 87.5% survival rate. Evidence of adaptive immunity (seroconversion) was identified in all surviving animals, though detection of F. tularensis with sensitivity to ceftobiprole in vitro in a limited number of treated and surviving animals indicates that the clinical efficacy of ceftobiprole medocaril may be enhanced by treatment durations greater than 10 days."

Journal • PK/PD data • Infectious Disease

Efficacy and Mechanism of Ceftobiprole in Treating Mycobacterium abscessusLung Disease (ChiCTR) - P=N/A | N=100 | Recruiting | Sponsor: Shenzhen Third People's Hospital; Shenzhen Third People's Hospital

New trial

Antimicrobial resistance among agents of hospital-acquired lower respiratory tract infection in the UK and Ireland: trends from 2008/2009 to 2018/2019. (PubMed, J Antimicrob Chemother) - "From 2008/09 to 2018/19, there were no major rises in resistance among the principal agents of HA-LRTI; for several important organisms/resistance combinations there were notable declines."

Journal • Infectious Disease • Pneumonia • Respiratory Diseases

Effect of antibiotics on Kupffer cell immunometabolism relative to intracellular killing of S. aureus using NAD(P)H fluorescence lifetime imaging. (PubMed, mBio) - "We investigated the immunometabolic effects of antistaphylococcal antibiotics (vancomycin, ceftobiprole, daptomycin, and tedizolid) on KCs relative to clearance of intracellular SA through gene expression analysis and optical metabolic imaging using fluorescence lifetime imaging microscopy. Vancomycin, however, did not affect KC metabolism and was unable to control bacterial growth inside the cells. These findings suggest that choosing antibiotics based on direct antimicrobial activity as well as indirect effects on host immune function could improve treatment outcomes for patients with S. aureus bloodstream infection."

Journal • Infectious Disease • Inflammation • Septic Shock

Individualized Precision Therapy With Ceftobiprole Guided by PK/PD in Geriatric Populations (clinicaltrials.gov) - P=N/A | N=150 | Not yet recruiting | Sponsor: Chinese PLA General Hospital

New trial

Ceftobiprole medocaril (Zevtera) - a new cephalosporin antibiotic. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Infectious Disease • Influenza • Respiratory Diseases

Management of MDR/XDR severe infections in the critically ill. (PubMed, Curr Opin Crit Care) - "Optimal management of serious infections by MDR/XDR pathogens requires up-to-date knowledge of evolving treatment options and resistance mechanisms. Further high-quality clinical trials are needed to guide evidence-based therapy."

Journal • Review • Infectious Disease • Pneumonia • Respiratory Diseases

Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Ceftobiprole Continuous Infusion Dosing Regimens for Patients with Staphylococcus aureus Bacteremia (SAB) (IDWeek 2025) - No abstract available

Clinical • PK/PD data • Infectious Disease

Should Ceftobiprole Replace Ceftaroline in the Management of Persistent Staphylococcal Bacteremia? - Con (IDWeek 2025) - No abstract available

Infectious Disease

Should Ceftobiprole Replace Ceftaroline in the Management of Persistent Staphylococcal Bacteremia? - Pro (IDWeek 2025) - No abstract available

Infectious Disease

64 - Out With the Old, in With the New: Time to Update the Management of Staphylococcus aureus Infections (IDWeek 2025) - "Learning Objectives: At the conclusion of this session, participants will be able to: compare and contrast vancomycin to other available agents in the management of invasive methicillin-resistant Staphylococcus aureus infections; defend the current place in therapy of vancomycin for methicillin-resistant Staphylococcal infections; select clinical situations where ceftobiprole may be considered over ceftaroline for invasive Staphylococcal infections; appraise the role of ceftaroline in the management of Staphylococcus aureus bacteremia."

Infectious Disease

Beta-lactams and beta-lactamase inhibitors-current developments (PubMed, Inn Med (Heidelb)) - "These included MRSA-active cephalosporins (ceftaroline and ceftobiprole), new, broadly effective combinations of beta-lactams with beta-lactamase inhibitors, and cefiderocol, a new siderophore cephalosporin that uses the bacteria's own iron uptake systems of gram-negative bacteria to better reach the site of action through the outer membrane.In addition to cefiderocol, the most important active ingredients or fixed combinations already available on the German market include ceftazidime-avibactam, ceftolozane-tazobactam, and aztreonam-avibactam. Imipenem-relebactam and meropenem-vaborbactam are also available; Cefepim-enmetazobactam was recently added...However, interesting new combinations, such as ceftibutene-avibactam for oral use, are in development. Such combinations could also enable the oral treatment of infections by some carbapenemase producers in the future."

Journal • Review • Infectious Disease

Gram-positive pathogens from Canadian hospitals: 17 years of results from the CANWARD study (2007-23). (PubMed, J Antimicrob Chemother) - "The CANWARD surveillance study has provided 17 years of reference antimicrobial susceptibility testing data on Gram-positive pathogens."

Journal • Critical care • Infectious Disease • Pneumococcal Infections • Pneumonia

Characterization of methicillin-resistant Staphylococcus aureus in Canadian hospitals: 17 years of the CANWARD study (2007-23). (PubMed, J Antimicrob Chemother) - "The changing epidemiology of MRSA in Canadian hospitals warrants continued national surveillance efforts as a resource to support therapeutic guidelines and infection control and prevention programmes."

Journal • Infectious Disease

Intrapulmonary concentrations of ceftobiprole high doses administered by continuous infusion in critically ill patients with community-acquired pneumonia. (PubMed, J Antimicrob Chemother) - "The use of high doses of ceftobiprole given by CI may be necessary to achieve PK/pharmacodynamic targets in ELF in critically ill patients with CAP and normal renal function, especially when less susceptible pathogen is suspected or identified."

Journal • Infectious Disease • Pneumonia • Respiratory Diseases

Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus of diverse genetic types. (PubMed, J Glob Antimicrob Resist) - "Ceftobiprole demonstrated higher activity than ceftaroline against a phylogenetically diverse set of MRSA isolates and may represent a preferred broad-spectrum antimicrobial choice for the treatment of MRSA infections."

Journal • Infectious Disease • Pneumonia • Respiratory Diseases

Paradoxical interaction between dalbavancin and β-lactams against endocarditis-associated Enterococcus faecalis clinical isolates. (PubMed, J Antimicrob Chemother) - "Dalbavancin exhibits poor activity against E. faecalis, and impairs the activity of β-lactams, especially amoxicillin. Dalbavancin should be used with caution in the treatment of E. faecalis infective endocarditis."

Journal • Cardiovascular

Nephrotoxicity of New Antibiotics: A Systematic Review. (PubMed, Toxics) - "The agents assessed included aztreonam/avibactam, cefepime/enmetazobactam, cefiderocol, ceftobiprole, contezolid, gepotidacin, imipenem/cilastatin/relebactam, lascufloxacin, lefamulin, levonadifloxacin, plazomicin, and sulbactam/durlobactam. There is a need for post-marketing studies to better characterize renal safety. Clinicians should remain vigilant and continue to monitor for and report renal-related adverse events."

Journal • Review

In vitro activity of ceftobiprole plus ampicillin against Enterococcus faecalis causing infective endocarditis: phenotypic and genotypic characterization. (PubMed, J Antimicrob Chemother) - "Ampicillin/ceftobiprole showed comparable in vitro activity to ampicillin/ceftriaxone against EFIE. Mutations in the promoter region of pbp4 could compromise the activity of the double β-lactam therapy. The study of ceftobiprole MIC together with DDST is an easy and useful methodology to detect isolates harbouring these mutations, with no synergism to β-lactam combinations."

Journal • Preclinical • Cardiovascular

Development of a Cyclodextrin-Based Drug Delivery System to Improve the Physicochemical Properties of Ceftobiprole as a Model Antibiotic. (PubMed, Int J Mol Sci) - "The most promising formulation was a ternary system of ceftobiprole, maleic acid, and SBE-β-CD (1:25:4 molar ratio), showing ~300-fold solubility improvement, low levels of degradation products, and stability after eight months at -20 °C. After pH adjustment to a parenterally acceptable level, the formulation demonstrated solubility and a pH comparable to the marketed drug product."

Journal

Stability of Ceftobiprole Medocaril in Portable Elastomeric Infusion Devices. (PubMed, Infect Dis Ther) - "Ceftobiprole medocaril is suitable for administration in OPAT at 6.25 mg/mL in sodium chloride 0.9% over 24 h at 25 °C using Accufuser® portable elastomeric infusion devices. These findings support the development of practical administration protocols for ceftobiprole medocaril in home-based antimicrobial therapy. Ceftobiprole medocaril is a new antibiotic used to treat serious infections. Because it was recently introduced, there is limited information about its stability when used for outpatient parenteral antimicrobial therapy (OPAT), a treatment that allows patients to receive intravenous antibiotics at home using portable elastomeric infusion devices. This study examined how stable ceftobiprole medocaril remains when stored and administered in portable elastomeric infusion devices. The antibiotic was diluted in two commonly used fluids (saline and dextrose) and kept at different temperatures: refrigerated (2-8 °C), room temperature..."

Journal • Infectious Disease

Use of Daptomycin to Manage Severe MRSA Infections in Humans. (PubMed, Antibiotics (Basel)) - "The data suggest that treatment with high-dose (8-10 mg kg⁻1) DAP shortened the time to blood-culture sterilisation by a median of 2 days compared with standard-dose vancomycin without increasing toxicity when model-informed area-under-the-curve monitoring was employed. Particular attention is given to the synergistic effects of DAP combined with fosfomycin or β-lactams, especially ceftaroline and ceftobiprole, in overcoming persistent and refractory MRSA infections; this approach results in a reduction in microbiological failure relative to monotherapy...Despite promising preclinical and clinical evidence supporting combination strategies, further randomized controlled trials are necessary to establish their definitive role in clinical practice, as are head-to-head cost-effectiveness evaluations. DAP remains a critical option in the evolving landscape of MRSA management, provided its use is integrated with precision dosing, resistance surveillance, and..."

Journal • Review • Infectious Disease